Reaction
Renal Cancer Metastatic reporting signals
As of the last recalculation, Renal Cancer Metastatic appears in 770 FAERS reports alongside 7 co-occurring drug terms. The strongest observed disproportionality signal is SUNITINIB MALATE (PRR 180.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sunitinib Malate | 196 | 180.4 | 181.3 |
| Pazopanib Hydrochloride | 90 | 101.7 | 102.0 |
| Axitinib | 46 | 67.8 | 68.0 |
| Cabozantinib | 56 | 33.9 | 33.9 |
| Sorafenib | 16 | 21.2 | 21.3 |
| Everolimus | 35 | 19.4 | 19.4 |
| Nivolumab | 31 | 9.0 | 9.0 |